AYTU

SEC source: 0001437749-26-025080 · rdgdoc.xml · nonDerivative · entry 1

Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,743

F1 · shares: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.

SEC source: 0001437749-26-025078 · rdgdoc.xml · nonDerivative · entry 1

LIU VIVIAN H · CIK 0001203467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,825

F1 · shares: Grant of restricted stock, which vest on July 28, 2027.

SEC source: 0001437749-26-025083 · rdgdoc.xml · nonDerivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 237,203

F1 · shares: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.

SEC source: 0001437749-26-025082 · rdgdoc.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,102

F1 · shares: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.

SEC source: 0001437749-26-025081 · rdgdoc.xml · nonDerivative · entry 1

Disbrow Jarrett · CIK 0001640724 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,568

F1 · shares: Grant of restricted stock, which vest as follows: 1/3 on July 28, 2027, with the remaining restricted stock vesting in 8 equal quarterly installments beginning October 28, 2027.

SEC source: 0001437749-26-025077 · rdgdoc.xml · nonDerivative · entry 1

JAIN ABHINAV · CIK 0001981291 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,500

F1 · shares: Grant of restricted stock, which vest on July 28, 2027.

SEC source: 0001437749-26-025076 · rdgdoc.xml · nonDerivative · entry 1

DOCKERY CARL · CIK 0001618149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,152

F1 · shares: Grant of restricted stock, which vest on July 28, 2027.

SEC source: 0001437749-26-025075 · rdgdoc.xml · nonDerivative · entry 1

Donofrio John Jr. · CIK 0001679841 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,762

F1 · shares: Grant of restricted stock, which vest on July 28, 2027.

SEC source: 0001437749-25-030645 · rdgdoc.xml · nonDerivative · entry 2

Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,743

F2 · shares: Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027.

SEC source: 0001437749-25-030645 · rdgdoc.xml · nonDerivative · entry 1

Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,243

F1 · shares: The reporting person was granted fully vested restricted stock in lieu of cash in satisfaction of their annual bonus.

SEC source: 0001437749-25-030639 · rdgdoc.xml · nonDerivative · entry 1

LIU VIVIAN H · CIK 0001203467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,825

F1 · shares: Grant of restricted stock, which vest on October 3, 2026.

SEC source: 0001437749-25-030650 · rdgdoc.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,102

F1 · shares: Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027.

SEC source: 0001437749-25-030648 · rdgdoc.xml · nonDerivative · entry 2

Disbrow Jarrett · CIK 0001640724 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,568

F2 · shares: Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027.

SEC source: 0001437749-25-030648 · rdgdoc.xml · nonDerivative · entry 1

Disbrow Jarrett · CIK 0001640724 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,068

F1 · shares: The reporting person was granted fully vested restricted stock in lieu of cash in satisfaction of their annual bonus.

SEC source: 0001437749-25-030642 · rdgdoc.xml · nonDerivative · entry 2

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 207,203

F2 · shares: Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027.

SEC source: 0001437749-25-030642 · rdgdoc.xml · nonDerivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,703

F1 · shares: The reporting person was granted fully vested restricted stock in lieu of cash in satisfaction of their annual bonus.

SEC source: 0001437749-25-030636 · rdgdoc.xml · nonDerivative · entry 1

JAIN ABHINAV · CIK 0001981291 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,500

F1 · shares: Grant of restricted stock, which vest on October 3, 2026.

SEC source: 0001437749-25-030634 · rdgdoc.xml · nonDerivative · entry 1

DOCKERY CARL · CIK 0001618149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,440

F1 · shares: Grant of restricted stock, which vest on October 3, 2026.

SEC source: 0001437749-25-030632 · rdgdoc.xml · nonDerivative · entry 1

Donofrio John Jr. · CIK 0001679841 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,762

F1 · shares: Grant of restricted stock, which vest on October 3, 2026.

SEC source: 0001437749-25-019958 · rdgdoc.xml · nonDerivative · entry 1

Disbrow Jarrett · CIK 0001640724 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,462

F1 · shares: Purchased pursuant to the Issuer's registered offering more particularly described on the Registration Statement on Form S-1, as amended, filed by the Issuer on June 2, 2025.

F2 · balance_after: Total reflects 1-to-20 reverse stock split effected by the Issuer on January 6, 2023.

SEC source: 0001437749-25-019956 · rdgdoc.xml · nonDerivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 153,257

F1 · shares: Purchased pursuant to the Issuer's registered offering more particularly described on the Registration Statement on Form S-1, as amended, filed by the Issuer on June 2, 2025.

SEC source: 0001104659-25-057852 · tm2517486-1_4seq1.xml · derivative · entry 1

Nantahala Capital Management, LLC · CIK 0001472322 · 10% owner

Harkey Wilmot B. · CIK 0001775952 · 10% owner

Mack Daniel · CIK 0001775831 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 4,815,217

Underlying: Common Stock · 4,000,000 shares

Expires not disclosed

F1 · derivative.exercise_date: Subject to certain limits on beneficial ownership, the Prefunded Warrants may be exercised to purchase Issuer Common Stock at an exercise price of $0.0001 per share. The Prefunded Warrants do not expire until exercised in full.

F1 · derivative.expiration_date: Subject to certain limits on beneficial ownership, the Prefunded Warrants may be exercised to purchase Issuer Common Stock at an exercise price of $0.0001 per share. The Prefunded Warrants do not expire until exercised in full.

F2 · ownership.nature: Nantahala Capital Management, LLC ("NCM"), an investment adviser to certain private funds and managed accounts (the "NCM Investors") that hold the Aytu BioPharma, Inc ("Issuer") securities disclosed in this Form 4, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.

SEC source: 0001437749-25-010224 · rdgdoc.xml · derivative · entry 2

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 209 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

F1 · derivative.exercise_date: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

F1 · derivative.expiration_date: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

SEC source: 0001437749-25-010224 · rdgdoc.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,602

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

SEC source: 0001437749-25-005873 · rdgdoc.xml · nonDerivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,591

F1 · shares: On February 28, 2025, Joshua R. Disbrow, purchased a total of 15,000 shares of common stock in multiple open market transaction at prices per share ranging from $1.29 to $1.30, with a weighted average price of approximately $1.30 per share. Mr. Disbrow undertakes to provide to AYTU BIOPHARMA, INC., any security holder of AYTU BIOPHARMA, INC., or the staff of the United States Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F1 · price: On February 28, 2025, Joshua R. Disbrow, purchased a total of 15,000 shares of common stock in multiple open market transaction at prices per share ranging from $1.29 to $1.30, with a weighted average price of approximately $1.30 per share. Mr. Disbrow undertakes to provide to AYTU BIOPHARMA, INC., any security holder of AYTU BIOPHARMA, INC., or the staff of the United States Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

SEC source: 0000912282-25-000223 · form4.xml · derivative · entry 2

Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Shares · 105 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units (RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025.

F1 · derivative.exercise_date: Restricted stock units (RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025.

F1 · derivative.expiration_date: Restricted stock units (RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025.

SEC source: 0000912282-25-000223 · form4.xml · nonDerivative · entry 1

Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units (RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted February 5, 2022, vesting quarterly beginning February 5, 2023, and ending February 5, 2025.

SEC source: 0000912282-25-000018 · form4.xml · derivative · entry 2

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 209

Underlying: Common Shares · 208 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

F1 · derivative.exercise_date: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

F1 · derivative.expiration_date: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

SEC source: 0000912282-25-000018 · form4.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,393

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

SEC source: 0000912282-24-000798 · form4.xml · nonDerivative · entry 1

Selhorn Ryan J · CIK 0001670673 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,895

F1 · shares: Represents shares of restricted stock which vest as follows: One-third on November 11, 2025; 1/12th of the original grant quarterly thereafter through November 11, 2027.

SEC source: 0000912282-24-000754 · form4.xml · nonDerivative · entry 1

LIU VIVIAN H · CIK 0001203467 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,825

F1 · shares: Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting.

SEC source: 0000912282-24-000764 · form4.xml · nonDerivative · entry 1

DOCKERY CARL · CIK 0001618149 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,440

F1 · shares: Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting.

SEC source: 0000912282-24-000762 · form4.xml · nonDerivative · entry 1

Donofrio John Jr. · CIK 0001679841 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,762

F1 · security: Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting.

F1 · shares: Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting.

F1 · ownership.direct: Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting.

F1 · ownership.nature: Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting.

SEC source: 0000912282-24-000760 · form4.xml · nonDerivative · entry 1

JAIN ABHINAV · CIK 0001981291 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,500

F1 · shares: Grant of restricted shares, which vest on the earlier of November 6, 2025, or at the Issuer's next annual stockholder meeting.

SEC source: 0000912282-24-000758 · form4.xml · derivative · entry 1

Disbrow Joshua R. · CIK 0001566240 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,000

Underlying: Common Shares · 38,000 shares

Expires 2034-11-06

F1 · derivative.exercise_date: The options vest as follows: 1/3 on November 6, 2025, with the remaining options vesting in 24 equal monthly installments beginning December 6, 2025.

SEC source: 0000912282-24-000756 · form4.xml · derivative · entry 1

Disbrow Jarrett · CIK 0001640724 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Shares · 7,000 shares

Expires 2034-11-06

F1 · derivative.exercise_date: The options vest as follows: 1/3 on November 6, 2025, with the remaining options vesting in 24 equal monthly installments beginning December 6, 2025.

SEC source: 0000912282-24-000750 · form4.xml · derivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Shares · 7,000 shares

Expires 2034-11-06

F1 · derivative.exercise_date: The options vest as follows: 1/3 on November 6, 2025, with the remaining options vesting in 24 equal monthly installments beginning December 6, 2025.

SEC source: 0000912282-24-000682 · form4.xml · derivative · entry 2

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 417

Underlying: Common Shares · 209 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

F1 · derivative.exercise_date: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

F1 · derivative.expiration_date: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

SEC source: 0000912282-24-000682 · form4.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,185

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

SEC source: 0000912282-24-000527 · form4.xml · derivative · entry 2

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 626

Underlying: Common Shares · 208 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

F1 · derivative.exercise_date: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

F1 · derivative.expiration_date: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

SEC source: 0000912282-24-000527 · form4.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,976

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

SEC source: 0001104659-24-072893 · tm2417545-2_4seq1.xml · derivative · entry 2

Nantahala Capital Management, LLC · CIK 0001472322 · 10% owner

Harkey Wilmot B. · CIK 0001775952 · 10% owner

Mack Daniel · CIK 0001775831 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 815,217

Underlying: Common Stock · 815,217 shares

Expires not disclosed

F3 · derivative.exercise_date: Subject to certain limits on beneficial ownership, the Exchange Warrants may be exercised to purchase Issuer Common Stock at an exercise price of $0.0001 per share. The Exchange Warrants do not expire until exercised in full.

F3 · derivative.expiration_date: Subject to certain limits on beneficial ownership, the Exchange Warrants may be exercised to purchase Issuer Common Stock at an exercise price of $0.0001 per share. The Exchange Warrants do not expire until exercised in full.

F2 · ownership.nature: Nantahala Capital Management, LLC ("NCM"), an investment adviser to certain private funds and managed accounts (the "NCM Investors") that hold the Aytu BioPharma, Inc ("Issuer") securities disclosed in this Form 4, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.

SEC source: 0001104659-24-072893 · tm2417545-2_4seq1.xml · derivative · entry 1

Nantahala Capital Management, LLC · CIK 0001472322 · 10% owner

Harkey Wilmot B. · CIK 0001775952 · 10% owner

Mack Daniel · CIK 0001775831 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

Underlying: Common Stock · 815,217 shares

Expires not disclosed

F1 · derivative.exercise_price: The Tranche B Warrants may be exercised for either shares of Common Stock or Exchange Warrants. Subject to certain limits on beneficial ownership, the Tranche B Warrants are exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Issuer's achievement of consolidated trailing twelve-month adjusted EBITDA of $12 million.

F1 · derivative.exercise_date: The Tranche B Warrants may be exercised for either shares of Common Stock or Exchange Warrants. Subject to certain limits on beneficial ownership, the Tranche B Warrants are exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Issuer's achievement of consolidated trailing twelve-month adjusted EBITDA of $12 million.

F1 · derivative.expiration_date: The Tranche B Warrants may be exercised for either shares of Common Stock or Exchange Warrants. Subject to certain limits on beneficial ownership, the Tranche B Warrants are exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Issuer's achievement of consolidated trailing twelve-month adjusted EBITDA of $12 million.

F1 · derivative.underlying: The Tranche B Warrants may be exercised for either shares of Common Stock or Exchange Warrants. Subject to certain limits on beneficial ownership, the Tranche B Warrants are exercisable at a price of $1.59 per share (or $1.5899 per Exchange Warrant). The Tranche B Warrants will expire upon the earlier of (x) five years after the date of issuance, and (y) 30 days following the Issuer's achievement of consolidated trailing twelve-month adjusted EBITDA of $12 million.

F2 · ownership.nature: Nantahala Capital Management, LLC ("NCM"), an investment adviser to certain private funds and managed accounts (the "NCM Investors") that hold the Aytu BioPharma, Inc ("Issuer") securities disclosed in this Form 4, may be deemed a beneficial owner of such securities. Each of Mr. Wilmot B Harkey and Mr. Daniel Mack may be deemed a beneficial owner of Issuer securities beneficially owned by NCM. Each of NCM, Mr. Harkey and Mr. Mack disclaims beneficial ownership of the Issuer's securities disclosed herein except to the extent of their respective pecuniary interests therein.

SEC source: 0000912282-24-000340 · form4.xml · derivative · entry 2

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 834

Underlying: Common Shares · 208 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

F1 · derivative.exercise_date: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

F1 · derivative.expiration_date: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

SEC source: 0000912282-24-000340 · form4.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,768

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest quarterly beginning March 31, 2023 and ending March 31, 2025.

SEC source: 0000912282-24-000006 · form4.xml · derivative · entry 2

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,042

Underlying: Common Shares · 209 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

F1 · derivative.exercise_date: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

F1 · derivative.expiration_date: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

SEC source: 0000912282-24-000006 · form4.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,560

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

SEC source: 0000912282-23-000399 · form4.xml · derivative · entry 2

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,251

Underlying: Common Shares · 208 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

F1 · derivative.exercise_date: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

F1 · derivative.expiration_date: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

SEC source: 0000912282-23-000399 · form4.xml · nonDerivative · entry 1

PYSZCZYMUKA GREG · CIK 0001952920 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,351

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs were granted on March 31, 2022, and vest as follows: One-third on March 31, 2023; 1/12th of the original grant quarterly thereafter through March 31, 2025. Settlement of vested RSUs will occur as soon as practicable following vesting.

SEC source: 0000912282-23-000317 · form4.xml · nonDerivative · entry 1

JAIN ABHINAV · CIK 0001981291 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

F1 · shares: Grant of restricted shares, which vest as follows: 1/3 on June 14, 2024, with the remaining restricted shares vesting in eight equal installments every three months, beginning on September 14, 2024.